Liver Health Shaper

In the third episode of "Liver Health Shaper," join host Jo Massoels, Chief Marketing Officer at Echosens, as we explore the pivotal role FibroScan® plays in the evolving landscape of liver health management. With the recent FDA approval of Rezdiffra™, the groundbreaking new treatment for MASH patients with moderate to advanced fibrosis, accurate, non-invasive diagnostics have never been more essential. Our distinguished guests, Dr. Naim Alkhouri, Chief Medical Officer at Arizona Liver Health, and Dr. Mazen Noureddin, Professor of Medicine and Director of the Houston Research Institute, discuss the new treatment and share their expert insights on how FibroScan®, equipped with advanced Guided VCTE™ technology, is transforming the way clinicians diagnose, monitor, and manage liver disease. They discuss the crucial role FibroScan® plays in identifying the right candidates for Rezdiffra™, as well as the role it plays in streamlining the prior authorization process.   Listeners will also learn how digital connectivity between FibroScan® and the Liver Health Management platform enhances clinical decision-making and improves patient care, making the future of liver health more accessible and efficient for both physicians and patients. Guests:Dr. Naim Alkhouri, Chief Medical Officer at Arizona Liver HealthDr. Mazen Noureddin, Professor of Medicine and Director of the Houston Research Institute Topics covered in the episode:The evolving role of FibroScan® in diagnosing and managing liver disease in light of a new, groundbreaking treatmentHow to navigate the prior authorization process for Rezdiffra™How Guided VCTE™ technology improves diagnostic precision and workflow efficiencyThe integration of FibroScan® with the Liver Health Management platform for better patient monitoringThe future of liver health management with non-invasive diagnostics at the forefrontHosted by Ausha. See ausha.co/privacy-policy for more information.

In the second episode of "Liver Health Shaper," join host Victor de Lédinghen, Chief Medical Officer at Echosens, as he dives into the groundbreaking advancements in liver health diagnostics with the next-generation FibroScan equipped with Guided VCTE technology. This episode features enlightening discussions with Dr. Raj Vuppalanchi, a hepatologist and Professor of Medicine at Indiana University School of Medicine, and Louise Campbell, Founder and Clinical Director at Tawazun Health. Together, they explore how this innovative technology enhances the accuracy and efficiency of liver assessments. They also discuss the critical role of non-invasive tools in managing and preventing widespread liver conditions such as MASLD and MASH, the potential hurdles in integrating these technologies into standard practice, and their impact on patient identification and treatment monitoring amidst evolving therapeutic landscapes.Guests:- Dr. Raj Vuppalanchi, Director of Hepatology at Indiana University School of Medicine- Louise Campbell, Founder and Clinical Director at Tawazun HealthTopics covered in the episode:- Introduction to the new Guided VCTE technology in FibroScan- Enhancements in diagnostic efficiency and accuracy- Impact on clinical workflow and decision-making- Role of non-invasive tools in the prevention and management of liver diseases- Future challenges and opportunities in liver health management- Influence on patient identification, access, and treatment monitoring in light of new drug approvalsHosted by Ausha. See ausha.co/privacy-policy for more information.

In the first episode of Liver Health Shaper, embark on an insightful journey into the realm of non-invasive liver diagnostics. This discussion navigates the transformative impact and advancements in liver health management.Host: Laurent Sandrin, founder of EchosensGuests:Professor Mazen Noureddin, Professor of Medicine and Director of the Houston Research Institute in HoustonLaurent Castera, Professor of Hepatology, Université Paris Cité, Beaujon Hospital in Paris, FranceTopics covered in the episode:The Role of FibroScan®Discussion on how FibroScan® has become a gold standard in the non-invasive assessment of chronic liver diseases.The impact of non-invasive solutions on clinical practice in the US and Europe.Importance of Early Screening and Comprehensive CareThe critical role of early screening in preventing advanced liver disease.The necessity for precise, reproducible measurements in liver disease management.Future Challenges and OpportunitiesInnovations in liver health management and their importance for the medical community.Upcoming therapeutics and the role of non-invasive diagnostics in patient identification and treatment monitoring.Each episode of Liver Health Shaper is a journey into the heart of non-invasive liver diagnostics and management, featuring the latest innovations and trends. Join us as we unpack insights and state-of-the-art advancements from leading specialists. This podcast is powered by Echosens.Hosted by Ausha. See ausha.co/privacy-policy for more information.